An Alternative Approach to Synthesize Sildenafil via Improved Copper-Catalyzed Cyclization-Reference-Cited by-同舟云学术

An Alternative Approach to Synthesize Sildenafil via Improved Copper-Catalyzed Cyclization

Published:2024-05-06 Issue:10 Volume:89 Page:7303-7311
ISSN:0022-3263
Container-title:The Journal of Organic Chemistry
language:en
Short-container-title:J. Org. Chem.

Author:

Odilov Abdullajon¹²^ORCID,Gong Xudong³,Qin Hongjian²⁴,Bonku Emmanuel Mintah¹²^ORCID,Zhu Fuqiang³,Yang Feipu¹^ORCID,Shen Jingshan¹²^ORCID

Affiliation:

1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

2. University of Chinese Academy of Sciences, Beijing 100049, P. R. China

3. Topharman Shanghai Company, Ltd., Shanghai 201203, P. R. China

4. Key Laboratory of Plant Resources and Chemistry in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, Xinjiang 830011, P. R. China

Funder

Science and Technology Commission of Shanghai Municipality

Alliance of International Science Organizations

Chinese Academy of Sciences

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.joc.4c00393

Reference32 articles.

1. The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction

2. Sildenafil for Pulmonary Arterial Hypertension

3. Babos, B. P. S. M. Sildenafil. StatPearls (updated February 14, 2023).

4. Global Erectile Dysfunction Drugs Market By Drug Type (Viagra, Cialis, Stendra/Spedra, Zydena, Levitra/Staxyn, Vitaros, and, Other Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment. Competition Scenario, Trends, and Forecast 2023–2032. https://market.us/report/erectile-dysfunction-drugs-market/#:~:text=Viagra%20(Sildenafil%20Citrate)%20holds%20a,market%20in%202022%20at%2051.7%25.

5. Bell, A. S.; Brown, D.; Terrett, N. K. Pyrazolopyrimidinone antianginal agents. BR9102560A, 1992.